{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058509","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.025075+00:00","generated_at":"2026-06-08T22:32:30.794564+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fulgent reports Q3 total revenue $85M, core revenue up 17% to $66M, GAAP loss $0.44/share","bullets":["Core revenue (ex-COVID) grew 17% YoY to $66M; total revenue $85M including $19M from COVID reimbursements.","GAAP net loss $13.1M ($0.44 EPS); non-GAAP loss $11.7M ($0.39 EPS) for Q3 2023.","Adjusted EBITDA was $18.1M; cash from operations $10.2M in the quarter.","Cash, cash equivalents, and marketable securities totaled $851M as of Sep 30, 2023.","Fulgent reiterates full-year 2023 core revenue guidance of $260M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058509","json":"https://secwatch.observer/filing/0000950170-23-058509.json","markdown":"https://secwatch.observer/filing/0000950170-23-058509.md","text":"https://secwatch.observer/filing/0000950170-23-058509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000095017023058509/0000950170-23-058509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000095017023058509/flgt-20231103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:32:30.794564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27d22eb9eb71e91e35348580de98f02d7482f1ad","claim":"Fulgent Genetics, Inc. reported third quarter ended September 30, 2023 results: revenue Total Revenue of $85 million, net income GAAP loss of $13.1 million, or $0.44 per share, EPS GAAP loss of $13.1 million, or $0.44 per share. Guidance reaffirmed.","evidence_excerpt":"Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023. Third Quarter 2023 Results: • Total Revenue of $85 million • Core Revenue 1 grew 17% year-over-year to $66 million • GAAP loss of $13.1 million, or $0.44 per share • Non-GAAP loss of $11.7 million, or $0.39 per share • Adjusted EBITDA of $18.1 million • Generated cash flow from operations of $10.2 million • Cash, cash equivalents, and investments in marketable securities of $851 million as of September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674930/000095017023058509/0000950170-23-058509-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"Total Revenue of $85 million"},{"label":"Net income","value":"GAAP loss of $13.1 million, or $0.44 per share"},{"label":"EPS","value":"GAAP loss of $13.1 million, or $0.44 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}